Grant of first POLB 001 cancer immunotherapy-induced CRS patent

/in

Significant milestone for Poolbeg’s global intellectual property portfolio 31 March 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from IP Australia, […]

Read more

Hansa Biopharma publishes 2025 Annual and Sustainability Reports

/in

Lund, Sweden, 26 March 2026. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: “2025 was a year of transformation for Hansa Biopharma, marked by the appointment of Renée Aguiar‑Lucander as our new CEO with a clear […]

Read more

Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs

/in

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering […]

Read more

Hansa Biopharma announces a USD 30 million convertible note financing

/in

Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Financing extends […]

Read more

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

/in

Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta Stockholm, Sweden, March 19, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal […]

Read more
© Optimum Strategic Communications.